Aprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It was determined that the substance was capable of demonstrating sedative, hypnotic, and anticonvulsant effects. A primary treatment indicated for the use of aprobarbital was subsequently insomnia. Aprobarbital was never as widely used as more common barbiturate derivatives such as phenobarbital and is now rarely prescribed.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aripiprazole | The metabolism of Aripiprazole can be increased when combined with Aprobarbital. |
| Aripiprazole lauroxil | The metabolism of Aripiprazole lauroxil can be increased when combined with Aprobarbital. |
| Buprenorphine | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Aprobarbital. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Aprobarbital. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Aprobarbital. |
| Hydrocodone | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Aprobarbital. |
| Magnesium sulfate | The therapeutic efficacy of Aprobarbital can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Aprobarbital may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Aprobarbital. |
| Mirtazapine | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Aprobarbital. |
| Orphenadrine | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Pramipexole | Aprobarbital may increase the sedative activities of Pramipexole. |
| Ropinirole | Aprobarbital may increase the sedative activities of Ropinirole. |
| Rotigotine | Aprobarbital may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Aprobarbital. |
| Suvorexant | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Aprobarbital. |
| Thalidomide | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Aprobarbital. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Aprobarbital. |
| Sodium oxybate | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Ifosfamide | The metabolism of Ifosfamide can be increased when combined with Aprobarbital. |
| Perampanel | The metabolism of Perampanel can be increased when combined with Aprobarbital. |
| Warfarin | The metabolism of Warfarin can be increased when combined with Aprobarbital. |
| Acenocoumarol | The metabolism of Acenocoumarol can be increased when combined with Aprobarbital. |
| (R)-warfarin | The metabolism of (R)-warfarin can be increased when combined with Aprobarbital. |
| R,S-Warfarin alcohol | The metabolism of R,S-Warfarin alcohol can be increased when combined with Aprobarbital. |
| S,R-Warfarin alcohol | The metabolism of S,R-Warfarin alcohol can be increased when combined with Aprobarbital. |
| (S)-Warfarin | The metabolism of (S)-Warfarin can be increased when combined with Aprobarbital. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Botulinum toxin type A. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Botulinum toxin type B. |
| Ethanol | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Aprobarbital. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Dapoxetine. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Alaproclate. |
| Naltrexone | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Bezitramide. |
| Morphine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Hydromorphone. |
| Oxycodone | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Sufentanil. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Dezocine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Aprobarbital is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Nicomorphine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Carfentanil, C-11. |
| Meperidine | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Meperidine. |
| Alfentanil | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Fentanyl. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Aprobarbital is combined with Levacetylmethadol. |